Binge Eating Disorder - Pipeline Review, H2 2013

Market: Pharmaceuticals and Healthcare

Global, 47 pages report, published by Global Markets Direct

Keywords : Binge Eating Disorder Therapeutic Products under Development, Key Players in Binge Eating Disorder Therapeutics, Binge Eating Disorder Pipeline Overview, Binge Eating Disorder Pipeline, Binge Eating Disorder Pipeline Assessment

Report ThumbnailSeptember-2013
Binge Eating Disorder - Pipeline Review, H2 2013

Summary

Global Markets Direct’s, 'Binge Eating Disorder - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Binge Eating Disorder, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Binge Eating Disorder. Binge Eating Disorder - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Binge Eating Disorder.
- A review of the Binge Eating Disorder products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Binge Eating Disorder pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Binge Eating Disorder.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Binge Eating Disorder pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
  • List of Figures
  • Number of Products under Development for Binge Eating Disorder, H2 2013 7
  • Products under Development for Binge Eating Disorder - Comparative Analysis, H2 2013 8
  • Products under Development by Companies, H2 2013 9
  • Late Stage Products, H2 2013 10
  • Mid Clinical Stage Products, H2 2013 11
  • Discovery and Pre-Clinical Stage Products, H2 2013 12
  • Assessment by Monotherapy Products, H2 2013 20
  • Assessment by Route of Administration, H2 2013 21
  • Assessment by Stage and Route of Administration, H2 2013 22
  • Assessment by Molecule Type, H2 2013 23
  • Assessment by Stage and Molecule Type, H2 2013 24
  • List of Tables
  • Number of Products Under Development for Binge Eating Disorder, H2 2013 7
  • Products under Development for Binge Eating Disorder - Comparative Analysis, H2 2013 8
  • Number of Products under Development by Companies, H2 2013 9
  • Comparative Analysis by Late Stage Development, H2 2013 10
  • Comparative Analysis by Mid Clinical Stage Development, H2 2013 11
  • Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2013 12
  • Products under Development by Companies, H2 2013 13
  • Products under Investigation by Universities/Institutes, H2 2013 14
  • Teva Pharmaceutical Industries Limited, H2 2013 15
  • Shire Plc, H2 2013 16
  • Omeros Corporation, H2 2013 17
  • Heptares Therapeutics Ltd., H2 2013 18
  • Lightlake Therapeutics Inc., H2 2013 19
  • Assessment by Monotherapy Products, H2 2013 20
  • Assessment by Stage and Route of Administration, H2 2013 22
  • Assessment by Stage and Molecule Type, H2 2013 24
  • Binge Eating Disorder Therapeutics - Drug Profile Updates 35
  • Binge Eating Disorder Therapeutics - Discontinued Products 41
  • Binge Eating Disorder Therapeutics - Dormant Products 42
  • Table of Contents
  • Table of Contents 2
  • List of Tables 4
  • List of Figures 4
  • Introduction 5
  • Global Markets Direct Report Coverage 5
  • Binge Eating Disorder Overview 6
  • Therapeutics Development 7
  • An Overview of Pipeline Products for Binge Eating Disorder 7
  • Binge Eating Disorder Therapeutics under Development by Companies 9
  • Late Stage Products 10
  • Comparative Analysis 10
  • Mid Clinical Stage Products 11
  • Comparative Analysis 11
  • Discovery and Pre-Clinical Stage Products 12
  • Comparative Analysis 12
  • Binge Eating Disorder Therapeutics - Products under Development by Companies 13
  • Binge Eating Disorder Therapeutics - Products under Investigation by Universities/Institutes 14
  • Companies Involved in Binge Eating Disorder Therapeutics Development 15
  • Teva Pharmaceutical Industries Limited 15
  • Shire Plc 16
  • Omeros Corporation 17
  • Heptares Therapeutics Ltd. 18
  • Lightlake Therapeutics Inc. 19
  • Binge Eating Disorder - Therapeutics Assessment 20
  • Assessment by Monotherapy Products 20
  • Assessment by Route of Administration 21
  • Assessment by Molecule Type 23
  • Drug Profiles 25
  • armodafinil - Drug Profile 25
  • Product Description 25
  • Mechanism of Action 25
  • R&D Progress 25
  • lisdexamfetamine dimesylate - Drug Profile 27
  • Product Description 27
  • Mechanism of Action 27
  • R&D Progress 27
  • OMS-527 - Drug Profile 30
  • Product Description 30
  • Mechanism of Action 30
  • R&D Progress 30
  • LT-12 - Drug Profile 32
  • Product Description 32
  • Mechanism of Action 32
  • R&D Progress 32
  • Drug Targeting Orexin 1 - Drug Profile 34
  • Product Description 34
  • Mechanism of Action 34
  • R&D Progress 34
  • Binge Eating Disorder Therapeutics - Drug Profile Updates 35
  • Binge Eating Disorder Therapeutics - Discontinued Products 41
  • Binge Eating Disorder Therapeutics - Dormant Products 42
  • Binge Eating Disorder - Product Development Milestones 43
  • Featured News & Press Releases 43
  • May 23, 2013: Lightlake Therapeutics Announces Presentation Of Binge Eating Disorder Treatment Phase II Trial Results At APA 2013 Annual Meeting 43
  • May 17, 2013: Shire To Present Scientific Data On Vyvanse At 166th APA Annual Meeting 2013 43
  • Mar 27, 2013: Lightlake Therapeutics Announces Phase II Clinical Trial Results Of Treatment For Binge Eating Disorder Accepted At American Psychiatric Association Annual Meeting 44
  • Appendix 46
  • Methodology 46
  • Coverage 46
  • Secondary Research 46
  • Primary Research 46
  • Expert Panel Validation 46
  • Contact Us 47
  • Disclaimer 47

Please select a license type

Share

Related Products

Global Markets DirectBinge Eating Disorder - Pipeline Review, H2 2013Product ThumbnailBinge Eating Disorder - Pipeline Review, H2 2013, Industry ReportProduct #: 113351
GlobalData
TeleResearch
Global Markets Direct
GBI Research
MarketsandMarkets
MicroMarketMonitor
PayPal Acceptance Mark
SSL Certificate
Copyright © 2017 Global Market Analyst. All Rights Reserved